ClinicalTrials.gg

Program

Lenalidomide

Also written as “lenalidomide”, “CC-5013” and “Drug: Carfilzomib + Lenalidomide + Dexamethasone”.

Its studies are mostly in Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Myelodysplastic Syndromes · Lymphoma, Non-Hodgkin · Lymphoma, Mantle-Cell, led by 6 companies.

Furthest: phase 4, since Mar 5, 200378 company-led studies, 3 open or runningNext primary completion: May 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb670 open or runningphase 3since Mar 5, 2003Aug 16, 2002none ahead
Takeda50 open or runningphase 4since May 30, 2017Jul 25, 2007none ahead
Oncotherapeutics32 open or runningphase 2since Jul 30, 2014Jul 30, 2014none ahead
bionor-immuno-as10 open or runningphase 2since Sep 11, 2012Sep 11, 2012none ahead
Samyang Biopharmaceuticals10 open or runningphase 1since Jun 25, 2017Jun 25, 2017none ahead
starton-therapeutics-inc11 open or runningphase 2since Sep 20, 2023Sep 20, 2023May 31, 2027phase 2 · NCT06087653

Also a collaborator on its studies: AbbVie, prologue-research-international, Karyopharm Therapeutics, Incyte, Johnson & Johnson, Abbott, icon-clinical-research and Hoffmann-La Roche.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Sep 10, 2005.

  1. Nov 4, 2014Phase 3 study in Lymphoma, Large B-Cell, DiffuseBristol-Myers Squibb · NCT02285062 · 570 enrolled · United States, Australia, Belgium and more
  2. Jan 23, 2015Phase 2 study in Multiple MyelomaBristol-Myers Squibb · NCT02348528 · 65 enrolled · China
  3. Aug 11, 2015Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT02521714 · 28 enrolled · United States
  4. Aug 25, 2015Phase 2 study in Leukemia, MyeloidBristol-Myers Squibb · NCT02538965 · 17 enrolled · United States, Canada
  5. Feb 16, 2016Phase 2 study in Multiple MyelomaBristol-Myers Squibb · NCT02685826 · 56 enrolled · United States, Canada, Denmark and more
  6. Sep 22, 2016Phase 2 study in Relapsed and/or Refractory Multiple MyelomaTakeda · NCT02917941 · 34 enrolled · Japan
  7. Feb 27, 2017Phase 1 study in Multiple MyelomaOncotherapeutics · NCT03110822 · 134 planned · United States
  8. May 30, 2017Phase 4 study in Multiple MyelomaTakeda · NCT03173092 · 141 enrolled · United States
  9. Jun 25, 2017Samyang Biopharmaceuticals's first study: phase 1 study in Healthy, MaleNew to Samyang BiopharmaceuticalsSamyang Biopharmaceuticals · NCT03208218 · 42 enrolled
  10. Jan 23, 2018Phase 4 study in Relapsed and/or Refractory Multiple MyelomaTakeda · NCT03416374 · 45 enrolled · Japan
  11. Aug 16, 2018Phase 3 study in Multiple MyelomaBristol-Myers Squibb · NCT03651128 · 386 enrolled · United States, Belgium, Canada and more
  12. Aug 12, 2020Phase 1 study in Multiple MyelomaOncotherapeutics · NCT04519476 · 22 planned · United States
  13. Dec 20, 2021Phase 4 study in Multiple MyelomaTakeda · NCT05183139
  14. Sep 20, 2023starton-therapeutics-inc's first study: phase 2 study in Multiple MyelomaNew to starton-therapeutics-incstarton-therapeutics-inc · NCT06087653 · 24 planned · United States

Ahead

  1. May 31, 2027Primary completion: phase 2 study in Multiple Myelomastarton-therapeutics-inc · NCT06087653

TargetBeta

“CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
pomalidomideruleBristol-Myers Squibbphase 451

Studies

The newest 60 of 78 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06087653Multiple Myeloma · United States2Recruitingstarton-therapeutics-incMay 31, 202724
NCT05183139Multiple Myeloma4WithdrawnTakedaDec 31, 20260
NCT04519476Multiple Myeloma · United States1RecruitingOncotherapeuticsDec 29, 202322
NCT03651128Multiple Myeloma · United States, Belgium, Canada and more3CompletedBristol-Myers SquibbApr 13, 2026386
NCT03416374Relapsed and/or Refractory Multiple Myeloma · Japan4CompletedTakedaMay 28, 202145
NCT03208218Healthy, Male1CompletedSamyang BiopharmaceuticalsAug 25, 201642
NCT03173092Multiple Myeloma · United States4TerminatedTakedaMar 30, 2026141
NCT03110822Multiple Myeloma · United States1RecruitingOncotherapeuticsSep 2024134
NCT02917941Relapsed and/or Refractory Multiple Myeloma · Japan2CompletedTakedaAug 31, 201934
NCT02685826Multiple Myeloma · United States, Canada, Denmark and more2CompletedBristol-Myers SquibbDec 15, 201756
NCT02538965Leukemia, Myeloid · United States, Canada2CompletedBristol-Myers SquibbJul 22, 201717
NCT02521714Healthy Volunteers · United States1CompletedBristol-Myers SquibbSep 23, 201528
NCT02348528Multiple Myeloma · China2CompletedBristol-Myers SquibbSep 29, 201665
NCT02285062Lymphoma, Large B-Cell, Diffuse · United States, Australia, Belgium and more3CompletedBristol-Myers SquibbMar 15, 2019570
NCT02206425Multiple Myeloma · United States2CompletedOncotherapeuticsJan 19, 201845
NCT02155634Multiple Myeloma3WithdrawnBristol-Myers SquibbApr 20170
NCT02112175Multiple Myeloma · Belgium, France, Greece and more3CompletedBristol-Myers SquibbOct 12, 202046
NCT01996865Lymphoma, Non-Hodgkin · United States, Germany, Puerto Rico3CompletedBristol-Myers SquibbMay 11, 2024503
NCT01938001Lymphoma, Non-Hodgkin · United States, Belgium, Brazil and more3CompletedBristol-Myers SquibbJun 22, 2018358
NCT01891643Newly Diagnosed, Previously Untreated Multiple Myeloma · United States, Greece, Italy and more3TerminatedBristol-Myers SquibbJun 25, 202023
NCT01724177Leukemia-Lymphoma, Adult T-Cell · Japan2CompletedBristol-Myers SquibbNov 20, 201426
NCT01698801Multiple Myeloma · Japan2CompletedBristol-Myers SquibbNov 26, 201326
NCT01704781Infections · Germany2Completedbionor-immuno-asAug 201436
NCT01593410Multiple Myeloma · China2CompletedBristol-Myers SquibbJan 3, 2013194
NCT01476787Lymphoma, Follicular · United States, Japan3CompletedBristol-Myers SquibbApr 30, 20241,030
NCT01358734Leukemia, Myeloid, Acute · United States, Canada2CompletedBristol-Myers SquibbMay 19, 201588
NCT01197560Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more3CompletedBristol-Myers SquibbJul 4, 2013111
NCT01169298Leukemia-Lymphoma, Adult T-Cell · Japan1CompletedBristol-Myers SquibbDec 1, 201313
NCT01032291Colorectal Neoplasms · Australia, Belgium, Germany and more2TerminatedBristol-Myers SquibbJan 201151
NCT01029262Anemia · United States, Australia, Austria and more3CompletedBristol-Myers SquibbMar 17, 2013239
NCT01021423Lymphoma, Mantle-Cell · United States, Czechia, France and more3TerminatedBristol-Myers SquibbMar 1, 20119
NCT00988208Prostatic Neoplasms · United States, Australia, Austria and more3CompletedBristol-Myers SquibbJan 13, 20121,059
NCT00975806Carcinoma, Renal Cell · United States2TerminatedBristol-Myers SquibbOct 1, 201116
NCT00963105Recurrence · United States, Canada, France and more2CompletedBristol-Myers SquibbSep 5, 2017104
NCT00928486Multiple Myeloma · Japan3CompletedBristol-Myers SquibbSep 10, 201025
NCT00910910Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3CompletedBristol-Myers SquibbMar 31, 2014450
NCT00910858Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS) · United States2CompletedBristol-Myers SquibbApr 200640
NCT00875667Lymphoma, Mantle-Cell · Belgium, Czechia, Denmark and more2CompletedBristol-Myers SquibbJun 28, 2018254
NCT00812968Myelodysplastic Syndromes · Japan2CompletedBristol-Myers SquibbSep 1, 201011
NCT00774345Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3CompletedBristol-Myers SquibbOct 27, 2020317
NCT00737529Lymphoma, Mantle-Cell · United States, Austria, Belgium and more2CompletedBristol-Myers SquibbApr 6, 2016134
NCT00689936Multiple Myeloma · United States, Australia, Austria and more3CompletedBristol-Myers SquibbJul 14, 20161,623
NCT00655668Lymphoma, T-Cell · United States, Australia, Belgium and more2TerminatedBristol-Myers SquibbMar 1, 201054
NCT00622336Multiple Myeloma · Russian Federation, Ukraine3CompletedBristol-Myers SquibbNov 25, 2013330
NCT00555100Multiple Myeloma · Japan1CompletedBristol-Myers SquibbDec 1, 201015
NCT00507442Multiple Myeloma · United States2CompletedTakedaOct 2010158
NCT00478777Recurrence · Germany3CompletedBristol-Myers SquibbNov 2007150
NCT00474188Lymphoma, Large B-Cell, Diffuse · United States, Australia, Canada2TerminatedBristol-Myers SquibbDec 200826
NCT00446433Crohn Disease · United States, France, Israel and more2CompletedBristol-Myers Squibb90
NCT00424047Multiple Myeloma · Australia, Austria, Belgium and more3CompletedBristol-Myers SquibbNov 1, 2005351
NCT00420849Multiple Myeloma · Australia, Austria, Ireland and more3CompletedBristol-Myers SquibbOct 2009587
NCT00419250Leukemia, Lymphocytic, Chronic, B-Cell · United States, Canada, Germany and more1CompletedBristol-Myers SquibbFeb 1, 201052
NCT00413036Lymphoma, Non-Hodgkin · United States, Canada, France and more2CompletedBristol-Myers SquibbApr 2011217
NCT00405756Newly Diagnosed Multiple Myeloma · Australia, Austria, Belarus and more3CompletedBristol-Myers SquibbNov 2009459
NCT00179751Pancreatic Neoplasms · United States2TerminatedBristol-Myers Squibb50
NCT00179738Prostatic Neoplasms · United States2TerminatedBristol-Myers Squibb40
NCT00179725Ovarian Neoplasms · United States2TerminatedBristol-Myers Squibb60
NCT00179712Ovarian Neoplasms · United States2CompletedBristol-Myers Squibb60
NCT00179699Carcinoma, Non-Small-Cell Lung · United States1TerminatedBristol-Myers Squibb40
NCT00179686Carcinoma, Non-Small-Cell Lung · United States2CompletedBristol-Myers Squibb40

How it is read

Names in the registry

  • “Lenalidomide”, 67 entries
  • “lenalidomide”, 16 entries
  • “CC-5013”, 14 entries
  • “Drug: Carfilzomib + Lenalidomide + Dexamethasone”, 1 entry
  • “Tafasitamab plus lenalidomide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.